TECLens and SERVImed Industrial Spa Announce Partnership to Pursue FDA Approval for Transepithelial Corneal Cross-Linking

Medical device manufacturer TECLens announced a partnership with Italian medical device maker SERVimed Industrial Spa aimed at the development and FDA approval of a new combination product to treat keratoconus. The new product under development will combine TECLens’ CXLens ‘on-eye’ cross-linking system for corneal remodeling with SERVImed’s trans-epithelial RIBOCROSS riboflavin drug formulation.

Terms of the deal were not disclosed.

TECLens and SERVImed will pursue FDA approval for the combination product of CXLens/RIBOCROSS to treat keratoconus that affects more than a million people in the United States. Like Avedro, SERVImed’s RIBOCROSS holds an FDA orphan drug designation for its proprietary riboflavin formulation for the treatment of keratoconus in patients undergoing cornea cross-linking procedures.

“The combination of SERVImed’s proven RIBOCROSS and TECLens’ proven CXLens will provide patients with a comfortable, noninvasive alternative to the treatment of ectatic disorders. Unlike any other cross-linking system, CXLens can treat both eyes simultaneously. Our combination product with RIBOCROSS will significantly increase clinical efficiency and procedure margin for physicians practicing corneal cross- linking,” TECLens CEO David Acker said in a company news release.

“We are very excited about this partnership, and strongly convinced that the combination of Teclens’ technology and SERVImed’s expertise will provide patients and physicians with an innovative, more efficient and safer corneal cross-linking procedure,” Servimed CEO Francesco Napolitano said in the news release.